Eiger BioPharmaceuticals Appoints David Apelian, MD, PhD, MBA Chief Operating Officer and Executive Medical Officer
"I am very pleased to have Dr. Apelian join the Eiger executive team as Chief Operating Officer and Executive Medical Officer," said
"I am very pleased to join Eiger's executive team at this exciting point in the Company's development, and look forward to working closely with Eiger management to advance a diverse set of exciting clinical stage orphan disease programs in therapeutic areas of high unmet medical need," said Dr. Apelian.
Dr. Apelian was most recently Executive VP and Chief Medical Officer of
Dr. Apelian completed his residency training in pediatrics at
About Eiger
Eiger is a clinical-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for orphan diseases. We are committed to translational innovation and developing well-characterized drugs acting on newly identified or novel, validated targets. Our mission is to systematically reduce the time and cost of the drug development process to more rapidly deliver important medicines to patients with orphan diseases. For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.
Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenue, projected expenses, prospects, plans and objectives, intentions, beliefs and expectations of management are forward-looking statements. These forward-looking statements may be accompanied by such words as "anticipate," "believe," "could," "estimate," "expect," "forecast," "intend," "may," "plan," "potential," "project," "target," "will" and other words and terms of similar meaning. Examples of such statements include, but are not limited to, whether or not the study results from the Phase 2 ULTRA study will be positive and whether ubenimex may be further developed and approved and whether promising earlier clinical study results will obtain in larger, later clinical studies, statements relating to the availability of cash for Eiger's future operations, Eiger's ability to develop its drug candidates for potential commercialization, the timing of the commencement and number and completion of Phase 2 trials and whether the products can be successfully developed or commercialized. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Eiger makes, including the risks described in the "Risk Factors" sections in the most recent Quarterly Report on Form 10-Q for the period ended
Investors:
Email: [email protected]
Phone: 1-650-619-6115
View original content with multimedia:http://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-appoints-david-apelian-md-phd-mba-chief-operating-officer-and-executive-medical-officer-300576766.html
SOURCE